Association between short term exposure to fine particulate matter and heart rate variability in older subjects with and without heart disease

J H Sullivan, A B Schreuder, C A Trenga, S L-J Liu, T V Larson, J Q Koenig, J D Kaufman


Background: Short term increases in exposure to particulate matter (PM) air pollution are associated with increased cardiovascular morbidity and mortality. The mechanism behind this effect is unclear, although changes in autonomic control have been observed. It was hypothesised that increases in fine PM measured at the subjects’ home in the preceding hour would be associated with decreased high frequency heart rate variability (HF-HRV) in individuals with pre-existing cardiac disease.

Methods: Two hundred and eighty five daily 20 minute measures of HRV (including a paced breathing protocol) were made in the homes of 34 elderly individuals with (n = 21) and without (n = 13) cardiovascular disease (CVD) over a 10 day period in Seattle between February 2000 and March 2002. Fine PM was continuously measured by nephelometry at the individuals’ homes.

Results: The median age of the study population was 77 years (range 57–87) and 44% were male. Models that adjusted for health status, relative humidity, temperature, mean heart rate, and medication use did not find a significant association between a 10 μg/m³ increase in 1 hour mean outdoor PM2.5 before the HRV measurement and a change in HF-HRV power in individuals with CVD (3% increase in median HF-HRV (95% CI –19 to 32)) or without CVD (5% decrease in median HF-HRV (95% CI –34 to 36)). Similarly, no association was evident using 4 hour and 24 hour mean outdoor PM2.5 exposures before the HRV measurement.

Conclusion: No association was found between increased residence levels of fine PM and frequency domain measures of HRV in elderly individuals.
disturbances. To optimise interpretation of HRV measurements we excluded individuals with atrial fibrillation, second degree heart block, left bundle branch block, paced rhythm, or known diabetes mellitus. Subjects were also excluded if they had unstable angina, MI, pneumonia, or an exacerbation of chronic obstructive pulmonary disease within 30 days of the study. No subject had a known MI within 18 months of the study.

HRV measurements

HRV was measured at the individual’s residence at the same time of day by trained study technicians. The measurements were performed after the subjects had rested in the supine position for 10 minutes. To diminish the effect of respiratory variation on HRV, participants followed a paced breathing protocol using audio cues at a respiratory rate of 12. The electrodes were placed in a modified V1–V5 position.

Processing of HRV measurements

A trained study technician reviewed and edited automatically determined readings of QRS complexes. Regions of artifact were eliminated. No recordings with more than 1% ectopic beats or 5% artifact were considered for analysis. After correction the cardiac rhythm data were analysed using Del Mar Dartscan software (Model DS-90, Irvine, CA, USA). Only normal-normal intervals between normal sinus rhythms with a successive N-N ratio of 0.8–1.2 were included for HRV analysis. The standard analysis included both time domain (SDNN, SDANN, r-MSSD) and frequency spectral measures (total power, high frequency (HF, 0.15–0.4 Hz), low frequency (LF, 0.04–0.15 Hz), and very low frequency (VLF, 0.01–0.04 Hz) HRV). The frequency measurement was obtained by performing a fast Fourier transformation method on 256 beat blocks sampled at 5 minute intervals using a Hamming windowed signal.

Exposure measures

The primary exposure metric was short term averaged (1, 4, and 24 hour averaged) fine PM measured by nephelometry (Radiance Research, Seattle, WA, USA) as a light scattering coefficient outside the participant’s residence. To allow for comparability with other studies we calibrated the nephelometric measure of PM against a gravimetric PM2.5 measure. This measure is referred to here as fine PM. Nephelometric data correlate well with gravimetric particle measurements in the 0.1–1.4 aerodynamic range. We also measured 1, 4, and 24 hour mean indoor fine PM by nephelometry at the subject’s residence. Outdoor nephelometric data were not measured for six individuals so we used the closest home outdoor nephelometer which was sited within 2 miles of the residences to capture local PM levels. A total of 28 days surrogate nephelometry exposure were used in our final analysis.

Statistical analysis

The data were analysed using SAS (Version 8.0, Cary, NC, USA). HRV power measures were log transformed before analyses.

A linear mixed model with random intercepts was used to determine the within individual effect of 1, 4, and 24 hour averaged outdoor PM on log transformed HF-HRV measures for individuals with and without heart disease. The final models were adjusted for age, mean resting heart rate, medication use, and meteorological variables (temperature and relative humidity as both linear and quadratic terms). The same models were repeated using indoor measures of fine PM. Individuals with COPD and healthy subjects were grouped as a non-CVD subgroup because of the small numbers.

<table>
<thead>
<tr>
<th>Variable</th>
<th>CVD (n = 21)</th>
<th>No CVD (n = 13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (range) age (years)</td>
<td>77 (57–85)</td>
<td>78 (72–87)</td>
</tr>
<tr>
<td>Sex (male)</td>
<td>9 (43%)</td>
<td>6 (46%)</td>
</tr>
<tr>
<td>Race (white)</td>
<td>20 (95%)</td>
<td>12 (92%)</td>
</tr>
<tr>
<td>History of MI</td>
<td>9 (43%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Current angina</td>
<td>6 (29%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Current CHF</td>
<td>3 (14%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Current hypertension</td>
<td>9 (43%)</td>
<td>6 (46%)</td>
</tr>
<tr>
<td>Medication use†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β blockers</td>
<td>12 (57%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>9 (43%)</td>
<td>4 (31%)</td>
</tr>
<tr>
<td>Calcium channel inhibitors</td>
<td>2 (10%)</td>
<td>2 (15%)</td>
</tr>
</tbody>
</table>

Table 1 Demographic data of study participants

CVD, cardiovascular disease; MI, myocardial infarction; CHF, congestive heart failure; ACE, angiotensin converting enzyme.

†Medication use adds up to more than 100% of the cardiac population as some individuals were on more than one class of medications.

To further explore whether autonomic imbalance was responsible for the PM effect, we similarly modelled the effect of 1, 4, and 24 hour mean outdoor and indoor nephelometry measures of PM on r-MSSD, SDNN, LF, and the LF:HF ratio of HRV.

RESULTS

HRV measurements were performed in individuals with and without CVD over 23 10 day study sessions. After editing, 285 HRV measurements were available in 34 individuals with (n = 21) and without (n = 13) CVD. After allowance for missing exposure data or unacceptable HRV measurements, a mean of six HRV measurements per individual was available for analysis in each study session.

The overall study population was older (median age 77 years (range 57–87)), predominantly white (94%), and 44% were male (table 1). The demographic factors of the CVD and non-CVD study populations did not differ. The CVD population comprised three individuals with CHF and 18 with documented ischaemic heart disease without overt CHF. Beta-blockers were used in 57% of individuals with heart disease. Fifteen individuals were on antihypertensive medications, nine in the CVD group and six in the non-CVD group.

Over the 23 study sessions there was a modest range of within session 1 hour averaged PM exposure (median 10.6 μg/m³, range 3.1–40.4; table 2). However, there was a relatively small range of 1 hour averaged exposure within individuals during each session (median 6.9 μg/m³, range 1.1–33.0; fig 1). Only 13 individuals (six in the CVD group and seven in the non-CVD group) experienced an in-session variation in 1 hour averaged PM2.5 exposure of more than 15 μg/m³. Table 3 shows the range of HRV measurements in those with and without CVD. There was a slightly lower ln HF-HRV power in those with CVD (5.0 (1.2) ms²) than in those without CVD (5.6 (1.1) ms²). The range of measurements is consistent with previous studies of HRV in elderly populations.

Final models adjusted for health status, relative humidity, temperature, and medication use did not find a significant association between a 10 μg/m³ increase in 1 hour mean outdoor PM2.5 preceding the HRV measurement and HF-HRV power in individuals with CVD (3% increase in median HF-HRV (95% CI −19 to 32)) or those without CVD (5% decrease in median HF-HRV (95% CI −34 to 36), table 4). A similar null association was evident using 4 hour and 24 hour mean outdoor PM2.5 exposures before the HRV measurement.
exposure variability during study sessions, dissimilarity in populations under study, or variation in the methods of HRV measurement.

Particulate matter in Boston and Baltimore is composed primarily of long range transport aerosols high in sulfate and trace metals. These particles may have a greater cardiovascular effect than combustion derived PM (wood smoke and vehicle emissions) which constitute the primary PM source in Seattle. Epidemiological studies have found a higher rate of cardiovascular mortality in the north eastern US (relative rate 0.6%) than in the western US (relative rate 0.2%). Studies in the north eastern US have reported an association between raised PM levels and onset of MI and AICD firings; however, case crossover analyses in Seattle were unable to replicate these associations.32 33 Furthermore, studies of hospital admissions for respiratory and cardiac diseases in eastern Canada suggest that PM with high sulfate composition has more deleterious cardiovascular effects than low sulfate PM.34-36 Moreover, in vitro and in vivo studies of PM stripped of the metal content found attenuation of both pulmonary and vascular inflammation37 and arrhythmogenic potential of PM.38-40 Finally, a single study in healthy aluminium workers suggests that the metal composition of PM influences cardiac autonomic function, measured by HRV.

Alternatively, our inability to detect changes in the HRV may have been due to the small range of PM exposure (median IQR 6 μg/m³) over each individual’s study session relative to the larger PM exposure range (median IQR 13–60 μg/m³) in previous studies which found a positive effect of PM on HRV measurements.41 42 A threshold level of PM exposure may be required to induce a measurable change in autonomic control of the heart. Concentrated ambient particle exposures to 40.5 (8.6) μg/m³ PM₂.₅ performed in North Carolina on 10 healthy elderly human volunteers resulted in a decrease in HF-HRV immediately after exposure.43 A recent investigation in a panel study of 88 elderly individuals in Utah by Pope estimated that a 100 μg/m³ increase in 24 hour averaged PM₂.₅ measured at central monitors resulted in a mean (SE) decline in r-MSSD of 42 (11) ms when contrasting low and high PM days in the same individual.44 Their study participants experienced a higher PM exposure (mean (SD) 23.5 (21) μg/m³) and the contrast in exposure between HRV measurements was much greater in these subjects, suggesting that their ability to detect an effect may be due to the greater exposure variability. Only six participants with CVD in our study experienced a variation in HRV as large as 15 μg/m³ PM₂.₅ over one 10 day study session. Moreover, 14 individuals were exposed to PM levels below 10 μg/m³ during their entire study session.

To compare the findings of this study with previous studies of the effect of PM exposure on HRV requires understanding the differences in protocols and study populations between studies.16-22 Unlike Gold and Pope, we chose a frequency domain analysis with focus on HF power. HF-HRV spectral

### Table 2 Summary of 1 hour mean outdoor exposure variables preceding HRV measurements

<table>
<thead>
<tr>
<th>Variable (unit)</th>
<th>Min</th>
<th>25%</th>
<th>50%</th>
<th>75%</th>
<th>90%</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>PM₂.₅ (μg/m³)†</td>
<td>3.3</td>
<td>8.0</td>
<td>10.7</td>
<td>15.6</td>
<td>20.9</td>
<td>40.3</td>
</tr>
<tr>
<td>CO (ppm)</td>
<td>0.63</td>
<td>0.99</td>
<td>1.22</td>
<td>1.51</td>
<td>1.81</td>
<td>2.50</td>
</tr>
<tr>
<td>NO₂ (ppm)</td>
<td>0.006</td>
<td>0.017</td>
<td>0.021</td>
<td>0.026</td>
<td>0.029</td>
<td>0.046</td>
</tr>
<tr>
<td>Temperature</td>
<td>33.5</td>
<td>40.9</td>
<td>46.4</td>
<td>53.3</td>
<td>61.3</td>
<td>69.3</td>
</tr>
<tr>
<td>Relative humidity</td>
<td>45.1</td>
<td>73.5</td>
<td>80.2</td>
<td>84.7</td>
<td>89.1</td>
<td>97.9</td>
</tr>
</tbody>
</table>

†Represents PM₂.₅ equivalent of actual nephelometric measure.

PM₂.₅ = (nephelometry measure/100 000 – 0.01)/0.28.

The median and mean values for the 4 and 24 hour exposures are similar to the 1 hour mean values.
analysis measurements may more accurately describe the autonomic contribution to cardiac oscillation than time domain measures in short term HRV recordings. Based on previous studies, we decided that a paced breathing protocol was essential to control for non-PM induced changes in vagal tone. We were unable to test whether the paced breathing protocol prevented small increases in the respiratory rate due to PM. Our results may differ as small changes in respiratory rate may have blunted the effect of PM on HF-HRV.

Panel studies by Liao et al. and Holguin et al. found that PM caused a decline in HF-HRV measurements but these studies either excluded or sampled small numbers of individuals with pre-existing heart disease. Such subjects are considered more susceptible to the effects of fine PM. Moreover, studies have shown that individuals with pre-existing cardiac disease have decreased baseline HF-HRV relative to healthy controls. Within these populations, decreased baseline HF-HRV is predictive of future cardiac events. Lastly, animals with pre-existing cardiac disease have increased PM induced cardiac arrhythmia and decreased time domain measures of HRV compared with healthy controls.

A recent large cross sectional study by Liao et al. of 4899 elderly individuals found a decrease of 0.06 ms² in HF-HRV for an 11 µg/m³ increase in PM₁₀ air pollution, which suggests that increased 24 hour mean PM levels result in declines in HF-HRV. Interestingly, those with pre-existing cardiac disease were at greatest risk. The cross sectional nature of their study precluded determining temporal relations between PM and HRV in susceptible individuals. However, their large sample permitted detection of very small declines in HF-HRV from ambient concentrations of PM. Despite their consistent findings of 24 hour mean levels of the effect of PM on HF-HRV, the small magnitude of the decline in HF-HRV is not likely to account for the increased incidence of cardiac events on higher air pollution days. Finally, differences between the studies in the primary end point (baseline differences in HF-HRV in their population compared with within person change in HF-HRV in our study) and exposure measures (central site measures of PM compared with residential levels in our study) do not allow for a simple comparison of study findings.

In contrast to the study by Holguin et al., our study included individuals receiving β blockers following MI. These drugs may have modulated the effect of PM on parasympathetic tone. A number of randomised clinical trials have found associations between the use of β blockers after MI and an increase in HF-HRV.

Potential strengths of our study include measures of HRV at the individual’s residence, analysis of short term effects of PM on HRV, and inclusion of individuals with and without heart disease. The residual measurements of PM allowed for more precise assessment of exposure and a comparison between the indoor and outdoor effects of PM.

Potential weaknesses of our study include the small sample size and little variation in daily PM levels within sessions. However, we had more HRV measurements and a larger number of subjects than previous studies which found an association between PM and HRV.

Current air pollution studies assume that daily alterations in HRV are associated with an increased risk of arrhythmia. However, there are no studies relating short term alterations (daily, weekly) in HRV measures and clinical cardiac events. It is probably an oversimplification to consider a single non-invasive measure of cardiac function as an explanation or surrogate for the mechanism of the contribution of PM to excess cardiac mortality. Alterations in HRV may only be a contributing factor or a signal of susceptibility to the effects of PM. Previous studies of sudden cardiac death document many potential pathways leading to arrhythmia. Moreover, studies of alterations in HRV measures before AICD discharge in individuals with cardiomyopathy suggest that the low frequency measures of HRV are increased in the minutes before discharge. This suggests a more complex balance of parasympathetic and sympathetic tone in modulating cardiac rhythm.

Our study was not able to detect a decrease in HRV in elderly individuals with and without known cardiac disease. However, we anticipate that future studies performed in larger populations with cardiac disease that combine multiple ECG measurements with systemic inflammatory and neurohormonal blood levels may detect potential pathways to account for the mechanism of the effect of PM in increasing mortality from cardiovascular disease. These studies should also be performed at a number of centres to determine whether the composition of PM influences the cardiac effect.

### Table 3: Comparison of mean (SE) heart rate and heart rate variability (HRV) measurements according to the presence or absence of known cardiovascular disease (CVD)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Non-CVD</th>
<th>CVD</th>
<th>Prior MI</th>
<th>Current CHF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting heart rate (beats/min)</td>
<td>72 (10)</td>
<td>72 (12)</td>
<td>70 (9)</td>
<td>75 (8)</td>
</tr>
<tr>
<td>ln LF-HRV (ms²)</td>
<td>5.0 (1.2)</td>
<td>4.2 (1.3)</td>
<td>4.6 (1.3)</td>
<td>3.8 (1.7)</td>
</tr>
<tr>
<td>ln HF-HRV (ms²)</td>
<td>5.6 (1.1)</td>
<td>5.0 (1.2)</td>
<td>5.1 (1.2)</td>
<td>4.9 (1.2)</td>
</tr>
<tr>
<td>ln RMSSD (ms)</td>
<td>3.7 (0.3)</td>
<td>3.7 (0.4)</td>
<td>3.7 (0.5)</td>
<td>3.6 (0.4)</td>
</tr>
<tr>
<td>ln SDNN (ms)</td>
<td>4.0 (0.3)</td>
<td>3.9 (0.4)</td>
<td>4.1 (0.3)</td>
<td>3.8 (0.4)</td>
</tr>
</tbody>
</table>

Heart rate is mean resting heart rate at time of HRV measurement.

### Table 4: Effect of a 10 µg/m³ increase in fine PM on HRV measurements in those with and without CVD adjusted for relative humidity, temperature, age, and medication use

<table>
<thead>
<tr>
<th>HRV measurements</th>
<th>Averaging time</th>
<th>CVD</th>
<th>Non-CVD</th>
</tr>
</thead>
<tbody>
<tr>
<td>ln HF-HRV</td>
<td>1 h</td>
<td>3 (19 to 32)</td>
<td>5 (34 to 36)</td>
</tr>
<tr>
<td></td>
<td>4 h</td>
<td>8 (16 to 38)</td>
<td>7 (36 to 34)</td>
</tr>
<tr>
<td></td>
<td>24 h</td>
<td>8 (19 to 43)</td>
<td>9 (40 to 40)</td>
</tr>
<tr>
<td>ln rmSSD</td>
<td>1 h</td>
<td>4 (11 to 4)</td>
<td>5 (8 to 20)</td>
</tr>
<tr>
<td></td>
<td>4 h</td>
<td>5 (12 to 3)</td>
<td>7 (6 to 23)</td>
</tr>
<tr>
<td></td>
<td>24 h</td>
<td>5 (13 to 3)</td>
<td>3 (11 to 21)</td>
</tr>
<tr>
<td>ln SDNN</td>
<td>1 h</td>
<td>2 (4 to 8)</td>
<td>1 (15 to 16)</td>
</tr>
<tr>
<td></td>
<td>4 h</td>
<td>3 (3 to 9)</td>
<td>1 (16 to 16)</td>
</tr>
<tr>
<td></td>
<td>24 h</td>
<td>1 (5 to 8)</td>
<td>1 (15 to 22)</td>
</tr>
</tbody>
</table>

Values are shown as percentage change from the median (95% CI).
REFERENCES

Association between short term exposure to fine particulate matter and heart rate variability in older subjects with and without heart disease

J H Sullivan, A B Schreuder, C A Trenga, S L-J Liu, T V Larson, J Q Koenig and J D Kaufman

Thorax 2005 60: 462-466
doi: 10.1136/thx.2004.027532

Updated information and services can be found at:
http://thorax.bmj.com/content/60/6/462

These include:

References
This article cites 34 articles, 14 of which you can access for free at:
http://thorax.bmj.com/content/60/6/462#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Epidemiologic studies (1829)
- Air pollution (110)
- Airway biology (1100)
- Environmental issues (253)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/